PRP176: The Impact of an Opioid Prescribing Limit Law on Prescription Rates in West Virginia
Treah Haggerty, MD; Patricia Dekeseredy, MSN, RN; Nathan Wood, MPH; Maryam Khodaverdi; Cara Sedney, MD, MA
Context: Approximately six percent of people in the US over the age of twelve misused prescription drugs in 2017. Multiple states have enacted legislation to reduce the volume of prescription opioids prescribed and misused. In West Virginia, the Opioid Reduction Act of 2018 (SB273), went into effect June 7th, 2018. Objective: The purpose of this study is to determine the impact of this legislation on opioid prescribing in West Virginia. Study Design: Quasi-experimental interrupted time series analysis. Setting or Dataset: The West Virginia Board of Pharmacy Prescription Drug Monitoring Program. Population studied: Opioid prescriptions filled in West Virginia from 64 weeks prior to enactment of SB273 to 64 weeks after the enactment of SB273. Outcome Measures: This study evaluated first-time opioid prescription rates, overall opioid prescription rates, average day supply, and milligram morphine equivalents (MME). Results: Expected results include change in first time opioid prescriptions, overall opioid prescriptions, average duration (in days’ supply) and average daily MME. ARIMA modeling will be used to detect a difference in pre-intervention prescribing and post-intervention prescribing. Conclusions: This study is evaluating the effects of the Opioid Reduction Act in West Virginia on first time opioid prescription, overall opioid prescriptions, average days supplied and daily MME. A downward trend was found in opioid prescriptions, however, this was present prior to legislative enactment and further studies are needed to understand the drivers of this trend.